Skip to content

Antiplatetelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Antiplatetelet therapy in PCI-treated ACS patients: The Rijnmond Collective Cardiology Research (CCR) Observational Study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON20101
Enrollment
4000
Registered
2012-11-14
Start date
2011-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acuut coronair syndroom Acute coronary syndrome

Interventions

There is no treatment intervention directed by the protocol in the CCR study. All treatment decisions are at the discretion of the treating physician in accordance with practice guideline recommendati

Sponsors

Vereniging Cardiologen Club Rijnmond Eli Lilly Nederland Grootslag 1-5, P.O box 379 NL - 3991 RA Houten THE NETHERLANDS Tel: +31 30 602 58 37 Fax: +31 30 602 58 88 Mob: +31 6 5382 6188
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis with NSTE-ACS or STEMI and treated with PCI during index hospitalization; 2. Age above 18 years.

Exclusion criteria

Exclusion criteria: Intolerance or allergy for aspirin, ticlopidine, clopidogrel or prasugrel.

Design outcomes

Primary

MeasureTime frame
Composite of all-cause mortality and nonfatal myocardial infarction.

Secondary

MeasureTime frame
1. All cause mortality; 2. Cardiovascular death; 3. Non fatal myocardial infarction; 4. Stroke; 5. Target vessel revascularization (TVR); 6. Stent thrombosis; 7. MACE (CV death/non-fatal MI/TVR); 8. Incidence of non-CABG-related TIMI major bleeding.

Contacts

Public ContactTuncay Yetgin

Department of Cardiology Erasmus MC

t.yetgin@erasmusmc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)